Gland Pharma Valuation Multiples

Gland Pharma Overview

About Gland Pharma

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.

Founded

1978

HQ

Employees

4.4K

Website

glandpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $690M

EBITDA: $168M

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Gland Pharma Financials

Gland Pharma reported last 12-month revenue of $690M and EBITDA of $168M.

In the same LTM period, Gland Pharma generated $448M in gross profit, $168M in EBITDA, and $103M in net income.

Gland Pharma P&L

In the most recent fiscal year, Gland Pharma reported revenue of $656M and EBITDA of $159M.

Gland Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Gland Pharma Stock Performance

Gland Pharma has current market cap of $3B, and enterprise value of $3B.

Gland Pharma's stock price is $19.32.

Gland Pharma Valuation Multiples

Gland Pharma trades at 4.2x EV/Revenue multiple, and 17.1x EV/EBITDA.

Gland Pharma Financial Valuation Multiples

As of April 18, 2026, Gland Pharma has market cap of $3B and EV of $3B.

Equity research analysts estimate Gland Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Gland Pharma has a P/E ratio of 30.9x.

Gland Pharma Margins & Growth Rates

Gland Pharma's revenue in the last 12 month grew by 14%.

Gland Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Gland Pharma's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Gland Pharma's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Gland Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Gland Pharma M&A Activity

Gland Pharma acquired XXX companies to date.

Last acquisition by Gland Pharma was on XXXXXXXX, XXXXX. Gland Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Gland Pharma Investment Activity

Gland Pharma invested in XXX companies to date.

Gland Pharma made its latest investment on XXXXXXXX, XXXXX. Gland Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).